Overview Request Sample Pages Request Customization Download PDF
You are viewing: Rest Of Latin America Biochips Market analysis
Part of: Biochips Market (Global)

The Rest Of Latin America Biochips Market was valued at $123.2 Million in 2025 and projected to reach to $173.5 Million by 2030, representing a compound annual growth rate of 7.1%. Rest Of Latin America's biochips market is positioned for moderate but sustainable growth over the next five years.

Rest Of Latin America Biochips Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Latin America Biochips Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 7.1% throughout the forecast period.
  • Rest Of Latin America is increasingly adopting biochip technologies across diagnostic, therapeutic, and research applications, driven by improving healthcare infrastructure and rising demand for personalized medicine solutions. The biochips market in Rest Of Latin America is benefiting from growing investments in healthcare innovation and expanding access to advanced diagnostic tools.
  • Rest Of Latin America's healthcare providers are recognizing the value of biochips in enabling rapid disease detection, drug development, and patient monitoring.
  • Between 2025 and 2030, Rest Of Latin America is expected to see accelerated adoption as regulatory frameworks mature and manufacturing capabilities expand across the region. Rest Of Latin America's market trajectory reflects broader Latin American trends toward modernization of healthcare systems and increased focus on precision medicine.
  • The region's biochips sector is positioned for sustainable growth as healthcare spending increases and awareness of biochip applications spreads among medical professionals and patients alike..

Key Market Statistics

  • CAGR (2025-2030) 7.1% CAGR
  • Market Size, 2025 ~USD 123.2 Million
  • Forecast, 2030 ~USD 173.5 Million
  • Country Rest Of Latin America

Rest Of Latin America Biochips Market Overview

Steady Regional Growth :

Rest Of Latin America's biochips market is projected to grow from $123.2 million in 2025 to $173.5 million by 2030, demonstrating consistent market expansion at a 7.1% CAGR throughout the forecast period.

Below-Global Growth Rate :

While the region shows solid growth, Rest Of Latin America's 7.1% CAGR trails the global biochips market CAGR of 8.8%, indicating slower adoption compared to more developed markets and emerging hubs.

Diverse Application Adoption :

Rest Of Latin America is increasingly implementing biochip technologies across diagnostic, therapeutic, and research applications, reflecting growing healthcare infrastructure investment and scientific advancement in the region.

Emerging Market Opportunity :

The region represents an untapped growth opportunity for biochip manufacturers and healthcare providers seeking to expand market presence in Latin America beyond major economies.

Rest Of Latin America Biochips Market Dynamics

  • The region's healthcare sector is gradually modernizing, with increased investment in diagnostic capabilities and research infrastructure driving biochip adoption.
  • Government initiatives promoting healthcare innovation and rising disease prevalence are key growth catalysts.
  • However, infrastructure limitations and cost constraints may moderate expansion compared to developed markets.
  • The forecast period will likely see growing interest from both public and private healthcare institutions seeking advanced diagnostic solutions..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Rest Of Latin America's biochips market is valued at $123.2 million in 2025 and is forecast to grow to $173.5 million by 2030, representing a 7.1% CAGR.
      • Rest Of Latin America is experiencing increased adoption of biochip technologies driven by improvements in healthcare infrastructure and demand for personalized medicine.
      • Rest Of Latin America's market growth is supported by expanding regulatory frameworks and emerging local manufacturing capabilities throughout the forecast period.
      • Rest Of Latin America's healthcare providers are increasingly investing in biochip solutions for diagnostics, therapeutics, and research applications.

      Biochips Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MICROFLUIDICS (Fabrication Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MICROARRAYS (Fabrication Technology)
      Market Size Base Year (Billions) ~USD 14.01 (2025)
      Revenue Forecast (Billions) ~USD 21.36 (2030)
      Segments Covered Products & Services, Type, Application, Fabrication Technology, End User, Product & Service

      Rest Of Latin America Biochips Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Products & Services

      • Consumables
      • Instruments
      • Software & Services

      By Type

      • Cell Arrays
      • Dna Chips
      • Lab-On-A-Chip
      • Protein Chips
      • Tissue Arrays

      By Application

      • Agricultural Biotechnology
      • Cancer Diagnosis & Treatment
      • Clinical Diagnostic
      • Diagnostics
      • Drug Discovery
      • Expression Profiling
      • Gene Expression
      • Genomics
      • High-Throughput Screening
      • Ivd & Poc
      • Other Dna Chip Applications
      • Other Loac Applications
      • Other Protein Chip Applications
      • Proteomics
      • Snp Genotyping

      By Fabrication Technology

      • Microarrays
      • Microfluidics

      By End User

      • Academic & Research Institutes
      • Biotechnology & Pharmaceutical Companies
      • Contract Research Organizations
      • Hospitals & Diagnostic Centers
      • Other End Users

      By Product & Service

      • Consumables
      • Instruments
      • Software & Services

      Target Audience

      • Biochip Manufacturers : Need Rest Of Latin America-specific market data to identify growth opportunities, assess regional demand for diagnostic and therapeutic biochips, and plan product localization strategies.
      • Healthcare Providers & Hospitals : Require market insights to understand biochip technology adoption trends in Rest Of Latin America, evaluate investment in diagnostic capabilities, and benchmark against regional peers.
      • Medical Device Distributors : Seek regional market intelligence to identify distribution opportunities, assess demand for biochip products, and develop sales strategies tailored to Rest Of Latin America's healthcare landscape.
      • Investment & Private Equity Firms : Need market forecasts and growth projections for Rest Of Latin America to evaluate investment opportunities in biochip companies and healthcare technology ventures in the region.
      • Research & Academic Institutions : Require market data to understand biochip research applications and adoption in Rest Of Latin America, supporting grant proposals and collaborative research initiatives in the region.

      Key Companies in the Rest Of Latin America Biochips Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects,
      JABILUnited StatesPublic CompanyRegulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem),
      AT&SCanadaPublic CompanyTurnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration,
      X-FABBelgiumPublic CompanyAutomotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes),
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other,
      10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents),
      CEPHEIDUnited StatesPrivate CompanyGeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
      REVVITYUnited StatesPublic CompanyDiagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions,

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.

      JABIL

      Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.

      AT&S

      AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      X-FAB

      X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.

      GE HEALTHCARE

      GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.

      QIAGEN

      Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ABBOTT

      Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.

      STANDARD BIOTOOLS

      Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.

      10X GENOMICS

      10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.

      CEPHEID

      Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.

      BIOMéRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.

      REVVITY

      Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.

      Reasons to Buy this Report

      • Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Latin America, enabling accurate budget allocation and investment decisions for regional expansion strategies.
      • Growth Trajectory Insights : Understand the 7.1% CAGR trajectory and $50.3 million growth opportunity between 2025-2030, helping identify optimal market entry and scaling timelines.
      • Competitive Positioning : Benchmark Rest Of Latin America's growth against the global 8.8% CAGR to identify competitive advantages and market gaps for differentiation strategies.
      • Application-Specific Demand : Access insights into diagnostic, therapeutic, and research biochip applications gaining traction in Rest Of Latin America to tailor product development and marketing.
      • Strategic Market Entry : Leverage region-specific data to develop targeted go-to-market strategies, partnership opportunities, and investment priorities for Rest Of Latin America operations.

      Frequently asked questions

      What is the current market size of biochips in Rest Of Latin America?

      Rest Of Latin America's biochips market is estimated at $123.2 million in 2025 and is projected to reach $173.5 million by 2030.

      What is the expected growth rate for biochips in Rest Of Latin America?

      Rest Of Latin America's biochips market is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2030.

      What are the primary drivers of biochips market growth in Rest Of Latin America?

      Rest Of Latin America's biochips market growth is driven by improving healthcare infrastructure, rising demand for personalized medicine, increased healthcare investments, and expanding regulatory frameworks.

      Which applications are driving biochips adoption in Rest Of Latin America?

      Rest Of Latin America is seeing increased adoption of biochips across diagnostic applications, therapeutic development, and research activities within healthcare institutions.

      How is Rest Of Latin America's biochips market positioned compared to other regions?

      Rest Of Latin America's biochips market is growing at a 7.1% CAGR, reflecting steady regional adoption as healthcare systems modernize and precision medicine awareness increases.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Biochips Market

      Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

      Note 2: Other designations include sales, marketing, and product managers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Biochips Market

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.

      Stakeholders

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Research Institutes
      • Academic Institutes
      • Contract Research Organizations
      • Research and Consulting Companies
      • Biochip Manufacturers and Distributors
      • DNA & Gene Chip Manufacturers and Distributors
      • Protein Microarray Manufacturers and Distributors
      • Lab-on-a-Chip Manufacturers and Distributors
      • Cell & Tissue Array Manufacturers and Distributors

      Report Objectives

      • To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
      • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

       

      Get the Full Biochips Market Report

      Full forecast, segment splits, and company analysis for all Biochips Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status